Search

The article presents a case study aimed to compare the efficacy between the combined induction of thalidomide, bortezomib and dexamethasone (VTD) with that of the combination adramycin, thalidomide and dexamethasone (ATD) induction in myeloma. The study is performed through a survival analysis done by univariate Cox regression wherein a Kaplan-Meier survival curve is derived. The results of the study show that VTD induction is superior than the ATD in terms of early and long-term efficacy.